PALI
PALISADE BIO, INC.
NASDAQ · Healthcare · Biotechnology · US
$1.34
−4.96%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.41
From 52W high−52.14%
Volume1.83M
Market cap$233.52M
P/E (TTM)—
P/S (TTM)467.0x
Div yield—
Key dataOct 19, 2026
Open
$1.41
From 52W high
−52.14%
Volume
1.83M
Market cap
$233.52M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.3x
P/E (TTM)
—
RSI (14)
36.8
MomentumView details →
1D Return
−4.96%
YTD Return
−41.91%
SummaryUpdated Jun 1, 2026
Palisade Bio, Inc. (NASDAQ:PALI) is a clinical-stage biopharmaceutical company founded in 2005 and headquartered in Carlsbad, California. The company went public in 2007 and focuses on developing oral therapies designed to protect the gastrointestinal tract's mucosal barrier during periods of intestinal stress. As a pre-revenue biotechnology company, Palisade Bio is currently advancing its lead drug candidate through clinical trials, targeting conditions where the protective lining of the digestive system becomes compromised due to reduced blood flow, infections, or surgical procedures.
Similar companies
Latest newsMore news →
PALISADE BIO, INC. presented five sets of clinical, pharmacokinetic, pharmacodynamic and mechanistic data on PALI-2108 at ACG 2026, including two presentations selected for Presidential Poster Awards.7d agoPalisade Bio announced it will present clinical and translational data for PALI-2108 in ulcerative colitis and Crohn's disease at UEG Week 2026.21d agoThe U.S. FDA cleared Palisade Bio's Investigational New Drug application for PALI-2108, enabling initiation of the Phase 2 ASCENTRA-CD trial in moderate to severe Crohn's disease.27d ago